Health
For Seniors with IBD, Think Safety with Treatments – MedPage Today
Hospitalizations risks were lower with vedolizumab than TNF inhibitors
Among older adults with inflammatory bowel disease (IBD), vedolizumab (Entyvio) appeared to be safer than tumor necrosis factor (TNF) inhibitors, a large retrospective study suggested.
After weighting using standardized mean differences, new users of vedolizumab had a lower likelihood of all-cause hospitalization during the 12 months after initiating biologic treatment compared with those starting TNF inhibitors, with a hazard ratio of 0.81 (95% CI 0.68-0.96), according to Bharati Kochar, MD, of…
-
General12 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General22 hours agoThree maps that show the scale of the NSW flood disaster
-
General12 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News21 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws